

Volume 17, 2006 Supplement 7

From Biomolecular and Technological Innovations to
Clinical Applications - 8th National GOIM Congress

18-21 June 2006, Messina, Italy

part I: invited papers

breast and ovarian cancer

From adjuvant to preventive breast cancer treatment:
bridging the gap over troubled waters

*E. Ricevuto, Z. C. Di Rocco, T. Sidoni, C. Ficarella,
G. Porzio, P. Pujol, B. Adamo, O. Majorana &
P. Marchetti*

vii5

Switching to anastrozole versus continued tamoxifen
treatment of early breast cancer. Updated results of the
Italian tamoxifen anastrozole (ITA) trial

*F. Boccardo, A. Rubagotti, P. Guglielmini, A. Fini,
G. Paladini, M. Mesiti, M. Rinaldini, S. Scali,
M. Porpiglia, C. Benedetto, N. Restuccia, F. Buzzi,
R. Franchi, B. Massidda, V. Distante, D. Amadori &
P. Sismondi*

viii0

Oral vinorelbine plus capecitabine (oral vincap)
combination in patients with advanced breast cancer
(ABC). A phase II study of the GOIM (Gruppo
Oncologico dell'Italia Meridionale)

*V. Lorusso, M. Spada, M. Giampaglia, A. Misino,
R. Calabrese, A. Latorre, G. Monticelli, M. Guida,
D. Sambiasi & G. Colucci*

viii5

Primary systemic therapy on local advance breast cancer,
where are we going?

S. Cinieri, L. Orlando & M. Colleoni

viii8

Taxane-containing chemotherapy in the treatment of
early breast cancer patients

M. Clavarezza, L. Del Mastro & M. Venturini

vii22

Nuclear and cytoplasmic interaction of pRb2/p130 and
ER-β in MCF-7 breast cancer cells

*M. Macaluso, M. Montanari, P. B. Noto, V. Gregorio,
E. Surmacz & A. Giordano*

vii27

Y179C, F486L and N550H are BRCA1 variants that may be
associated with breast cancer in a Sicilian family: results
of a 5-year GOIM (Gruppo Oncologico dell'Italia
Meridionale) prospective study

*C. Augello, L. Bruno, V. Bazan, V. Calò, V. Agnese, S. Corsale,
S. Cascio, G. Gargano, M. Terrasi, F. Barbera, S. Fricano,
B. Adamo, M. R. Valerio, G. Colucci, E. Sumarcz & A. Russo*

vii30

BRCA1 and BRCA2 genetic testing in Italian breast
and/or ovarian cancer families: mutation spectrum and

prevalence and analysis of mutation prediction models

*C. Capalbo, E. Ricevuto, A. Vestri, E. Ristori, T. Sidoni,
O. Buffone, B. Adamo, E. Cortesi, P. Marchetti, G. Scambia,
S. Tomao, C. Rinaldi, M. Zani, S. Ferraro, L. Frati,
I. Screpanti, A. Gulino & G. Giannini*

vii34

Detection and quantification of mammaglobin in the
blood of breast cancer patients: can it be useful as a
potential clinical marker? Preliminary results of a
GOIM (Gruppo Oncologico dell'Italia Meridionale)
prospective study

*G. Gargano, V. Agnese, V. Calò, S. Corsale, C. Augello,
L. Bruno, L. La Paglia, A. Gullo, L. Ottini, A. Russo,
F. Fulfaro, G. Rinaldi, A. Crosta, G. Cicero, O. Majorana,
L. Palmeri, C. Cipolla, A. Agrusa, G. Gulotta, V. Morello,
G. Di Fede, V. Adamo, G. Colucci, R. M. Tomasino,
M. R. Valerio, V. Bazan & Antonio Russo*

vii41

From bio-molecular and technology innovations to clinical
practice: focus on ovarian cancer

F. Legge, G. Ferrandina & G. Scambia

vii46

Medical treatment of resistant or recurrent epithelial
ovarian cancer

*S. Pignata, C. Pisano, M. Di Maio, F. Iodice, G. Casella,
G. Laurelli, S. Greggi & R. V. Iaffaioli*

vii49

gastro-intestinal cancer

New strategies in colon cancer adjuvant therapy

R. Labianca, S. Mosconi & M. C. Garassino

vii51

FOLFIRI with or without celecoxib in advanced colorectal
cancer: a randomized phase II study of the Gruppo
Oncologico dell'Italia Meridionale (GOIM)

*E. Maiello, F. Giuliani, V. Gebbia, N. Di Renzo, G. Pezzella,
S. Romito, R. Mallamaci, M. Lopez & G. Colucci*

vii55

Raltitrexed plus levofolinic acid and bolus/continuous
infusion 5-fluorouracil on a biweekly schedule for elderly
patients with advanced colorectal carcinomas

*V. Gebbia, F. Verderame, F. Ferraiù, R. Bordonaro,
A. Callari, M. Caruso, M. L. Tirrito, R. Valenza, G. Cicero,
N. Borsellino & P. Tralongo*

vii60

Cetuximab for treatment of metastatic colorectal cancer

*G. Cerea, R. Ricotta, I. Schiavetto, M. R. Maugeri,
A. Sartore-Bianchi, M. Moroni, S. Artale & S. Siena*

vii66

Continued overleaf

Gemcitabine and oxaliplatin combination chemotherapy in advanced biliary tract cancers <i>F. Verderame, A. Russo, R. Di Leo, G. Badalamenti, D. Santangelo, G. Cicero, M. R. Valerio, G. Gulotta, G. Tomasello, N. Gebbia & F. Fulfarò</i>	vii68	biomolecular therapy: open questions and future directions	
Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM) <i>F. Giuliani, V. Gebbia, E. Maiello, N. Borsellino, E. Bajardi & G. Colucci</i>	vii73	Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy <i>F. Ciardiello, T. Troiani, R. Bianco, M. Orditura, F. Morgillo, E. Martinelli, M. P. Morelli, T. Cascone & G. Tortora</i>	vii109
Novel P53 mutations detected by FAMA in colorectal cancers <i>F. De Galitiis, K. Cannita, A. Tessitore, F. Martella, Z. C. Di Rocco, A. Russo, V. Adamo, S. Iacobelli, S. Martinotti, P. Marchetti, C. Ficorella & E. Ricevuto</i>	vii78	Apoptosis: a relevant tool for anticancer therapy <i>A. Russo, M. Terrasi, V. Agnese, D. Santini & V. Bazan</i>	vii115
Molecular detection of TP53, Ki-Ras and p16 ^{INK4A} promoter methylation in plasma of patients with colorectal cancer and its association with prognosis. Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study <i>V. Bazan, L. Bruno, C. Augello, V. Agnese, V. Calò, S. Corsale, G. Gargano, M. Terrasi, V. Schirò, G. Di Fedè, V. Adamo, C. Intrivici, A. Crosta, G. Rinaldi, F. Latteri, G. Dardanoni, N. Grassi, M. R. Valerio, G. Colucci, M. Macaluso & A. Russo</i>	vii84	Targeting Raf-kinase: molecular rationales and translational issues <i>M. Caraglia, P. Tassone, M. Marra, A. Budillon, S. Venuta & P. Tagliaferri</i>	vii124
Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin <i>F. Bishehsari, M. Mahdavinia, R. Malekzadeh, F. Verginelli, T. Catalano, M. Sotoudeh, V. Bazan, V. Agnese, L. De Lellis, D. Esposito, D. Semeraro, G. Colucci, N. Rakhshani, A. Cama, M. Piantelli, S. Iacobelli, A. Russo & R. Mariani-Costantini</i>	vii91	Methodology of clinical trials with new molecular-targeted agents: where do we stand? <i>A. Morabito, M. Di Maio, E. De Maio, N. Normanno & F. Perrone</i>	vii128
Patterns of genomic instability in gastric cancer: clinical implications and perspectives <i>L. Ottini, M. Falchetti, R. Lupi, P. Rizzolo, V. Agnese, G. Colucci, V. Bazan & A. Russo</i>	vii97	miscellaneous cancer: from adjuvant to preventive	
Gastric adenomas: relationship between clinicopathological findings, <i>Helicobacter pylori</i> infection, APC mutations and COX-2 expression <i>A. Rocco, R. Caruso, S. Toracchio, L. Rigolid, F. Verginelli, T. Catalano, M. Neri, M. C. Curia, L. Ottini, V. Agnese, V. Bazan, A. Russo, G. Pantuso, G. Colucci, R. Mariani-Costantini & G. Nardone</i>	vii103	Postchemotherapy residual masses in germ cell tumor patients: our experience <i>F. Morelli, L. Tozzi, P. Setola, M. Bisceglia, V. Ricci Barbini & E. Maiello</i>	vii132
		Significance of P16 ^{INK4A} hypermethylation gene in primary head/neck and colorectal tumors: it is a specific tissue event? Results of a 3-year GOIM (Gruppo Oncologico dell'Italia Meridionale) prospective study <i>V. Agnese, S. Corsale, V. Calò, C. Augello, L. Bruno, D. Calcara, A. Crosta, V. Rodolico, G. Rinaldi, G. Cicero, F. Latteri, A. Agrusa, V. Morello, V. Adamo, G. Altavilla, G. Di Fedè, E. Fiorentino, N. Grassi, M. A. Latteri, M. R. Valerio, R. M. Tomasino, G. Colucci, V. Bazan & A. Russo</i>	vii137
		part II: abstracts	
		Session A: Breast cancer	vii142
		Session B: Gastrointestinal cancer	vii148
		Session C: Head and Neck	vii151
		Session D: Melanoma cancer	vii152
		Session E: Ovarian/Prostate cancer	vii153
		Session F: Miscellaneous cancer	vii155
		author index	vii164